Bristol Myers touts PhIII Opdivo win in urothelial carcinoma; Liminal BioSciences goes private

Bris­tol My­ers Squibb said Tues­day that a sub-study of a Phase III tri­al test­ing Op­di­vo with cis­platin-based chemother­a­py, fol­lowed by Op­di­vo monother­a­py, met the pri­ma­ry end­points of over­all sur­vival and pro­gres­sion-free sur­vival.

The sub-study was in pa­tients with un­re­sectable or metasta­t­ic urothe­lial car­ci­no­ma as a first-line treat­ment, ran­dom­iz­ing 608 pa­tients to ei­ther re­ceive Op­di­vo with chemo every three weeks or chemother­a­py on­ly. Ef­fi­ca­cy mea­sures were met, and the com­pa­ny added that the com­bi­na­tion had a “tol­er­a­ble safe­ty pro­file.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN